386 related articles for article (PubMed ID: 31552448)
1. Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.
Davis AK; Pratt WB; Lieberman AP; Osawa Y
Cell Mol Life Sci; 2020 Mar; 77(6):977-996. PubMed ID: 31552448
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.
Margulis BA; Vigont V; Lazarev VF; Kaznacheyeva EV; Guzhova IV
FEBS Lett; 2013 Jun; 587(13):1997-2007. PubMed ID: 23684638
[TBL] [Abstract][Full Text] [Related]
3. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease.
Duncan EJ; Cheetham ME; Chapple JP; van der Spuy J
Subcell Biochem; 2015; 78():243-73. PubMed ID: 25487025
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease.
Guzhova IV; Lazarev VF; Kaznacheeva AV; Ippolitova MV; Muronetz VI; Kinev AV; Margulis BA
Hum Mol Genet; 2011 Oct; 20(20):3953-63. PubMed ID: 21775503
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation.
Chafekar SM; Wisén S; Thompson AD; Echeverria A; Walter GM; Evans CG; Makley LN; Gestwicki JE; Duennwald ML
ACS Chem Biol; 2012 Sep; 7(9):1556-64. PubMed ID: 22709427
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Reis SD; Pinho BR; Oliveira JMA
Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
[TBL] [Abstract][Full Text] [Related]
7. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
8. The potential of indole and a synthetic derivative for polyQ aggregation reduction by enhancement of the chaperone and autophagy systems.
Lin CH; Wu YR; Kung PJ; Chen WL; Lee LC; Lin TH; Chao CY; Chen CM; Chang KH; Janreddy D; Lee-Chen GJ; Yao CF
ACS Chem Neurosci; 2014 Oct; 5(10):1063-74. PubMed ID: 25197952
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamine aggregation in Huntington and related diseases.
Polling S; Hill AF; Hatters DM
Adv Exp Med Biol; 2012; 769():125-40. PubMed ID: 23560308
[TBL] [Abstract][Full Text] [Related]
10. HSP70-HSP90 Chaperone Networking in Protein-Misfolding Disease.
Prodromou C; Aran-Guiu X; Oberoi J; Perna L; Chapple JP; van der Spuy J
Subcell Biochem; 2023; 101():389-425. PubMed ID: 36520314
[TBL] [Abstract][Full Text] [Related]
11. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation.
Wang AM; Miyata Y; Klinedinst S; Peng HM; Chua JP; Komiyama T; Li X; Morishima Y; Merry DE; Pratt WB; Osawa Y; Collins CA; Gestwicki JE; Lieberman AP
Nat Chem Biol; 2013 Feb; 9(2):112-8. PubMed ID: 23222885
[TBL] [Abstract][Full Text] [Related]
12. Autophagy and Polyglutamine Disease.
Ren H; Hao Z; Wang G
Adv Exp Med Biol; 2020; 1207():149-161. PubMed ID: 32671744
[TBL] [Abstract][Full Text] [Related]
13. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases.
Pratt WB; Gestwicki JE; Osawa Y; Lieberman AP
Annu Rev Pharmacol Toxicol; 2015; 55():353-71. PubMed ID: 25292434
[TBL] [Abstract][Full Text] [Related]
14. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.
Fujikake N; Nagai Y; Popiel HA; Okamoto Y; Yamaguchi M; Toda T
J Biol Chem; 2008 Sep; 283(38):26188-97. PubMed ID: 18632670
[TBL] [Abstract][Full Text] [Related]
15. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
Nagai Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
[TBL] [Abstract][Full Text] [Related]
16. Class-specific interactions between Sis1 J-domain protein and Hsp70 chaperone potentiate disaggregation of misfolded proteins.
Wyszkowski H; Janta A; Sztangierska W; Obuchowski I; Chamera T; Kłosowska A; Liberek K
Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34873058
[TBL] [Abstract][Full Text] [Related]
17. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Nagai Y; Fujikake N; Popiel HA; Wada K
Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
[TBL] [Abstract][Full Text] [Related]
18. Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome.
Shiber A; Ravid T
Biomolecules; 2014 Jul; 4(3):704-24. PubMed ID: 25036888
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Sti1 in spatial quality control of amyloid-like proteins.
Wolfe KJ; Ren HY; Trepte P; Cyr DM
PLoS One; 2014; 9(5):e95914. PubMed ID: 24828240
[TBL] [Abstract][Full Text] [Related]
20. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
Maiti P; Manna J; Veleri S; Frautschy S
Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
